Central Nervous System Lymphoma
Conditions
Keywords
Relapse refractory, Selinexor, ATG-010, Primary Central Nervous System Lymphoma（PCNSL）, Secondary Central Nervous System Lymphoma（SCNSL）
Brief summary
This is a single-arm and open-label study to explore X+MTX+Ritu (ATG-010, Methotrexate, Rituximab) regimen in Relapse refractory PCNSL patients. Approximately 30 patients will be enrolled in the study. In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen and escalating doses of oral ATG-010 weekly in a 3+3 design. Then a phase 2 expansion at the recommended dose level based on phase 1b trial will be conducted to evaluate the efficacy, safety and tolerability.
Detailed description
In dose escalation phase, patients with Relapse refractory PCNSL will be treated with X+MTX+Ritu regimen （Methotrexate 3.5 g/m2, d1; Rituximab 375 mg/m2, d0）and escalating doses of oral ATG-010 weekly in a 3+3 design. ATG-010 dose level (DL) 1, 2 and 3 are 60, 80 and 100mg respectively respectively on day 1,8,15,22 for 28-days cycle. The phase 2 expansion at the recommended dose level based on phase 1b trial. The total 6 cycles, 28 days per cycle . And, Subjects participating in the study will undergo a screening period（up to 21days）, a treatment period, and a follow-up period. The screening period is a maximum of 21 days before treatment period, And will be followed by 6 cycles of combination treatment（28 days per cycle）. partial remission(PR) patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death.
Interventions
DRUGSelinexor
Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor. PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death.
DRUGRituximab
Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
DRUGMethotrexate
high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
Sponsors
Antengene Corporation
Tong Chen, MD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients must meet all of the following inclusion criteria to be eligible to enroll in this study: 1. Participants must be able to understand and be willing to sign a written informed consent document. 2. Men and woman who are 18-75 years old on the day of consenting to the study. 3. Histologically documented PCNSL and SCNSL secondary to histologically documented systemic diffuse large B-cell lymphoma (DLBCL). 4. Patients must have relapsed/refractory PCNSL or relapsed/refractory SCNSL. 5. Patients must have response or remain stable disease for 2 months to prior methotrexate-based regimen. 6. Patients who had prior autologous hematopoietic stem cell transplantation are eligible. 7. Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 28 days prior to cycle1 day 1(C1D1). For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells. 8. Participants must have an Eastern Cooperative Oncology Group performance status of 0-3. 9. Participants must have adequate bone marrow and organ function shown by: 1. Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9/L 2. Platelets ≥ 75 x 10\^9/L and no platelet transfusion within the past 14 days prior to study registration c Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 14 days prior to study registration 10. International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal. 11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal. 12. Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome. 13. Calculated creatinine clearance(CrCl)≥50ml/min using the Cockcroft-Gault equation or 24-hour urine collection. 14. Life expectancy of \> 3 months.
Exclusion criteria
1. Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded. 2. Lymphoma patients with only intraocular involvement. 3. Pathological diagnosis of PCNSL is T-cell lymphoma. 4. Patients with disease progression within 6 months of prior methotrexate-containing regimen. 5. patients only had received stereotactic radiation therapy as prior treatment. 6. Patients have received chemotherapy, monoclonal antibodies or targeted anticancer therapy within 21 days or 5 half-lives, whichever is shorter, prior to C1D1. 7. Patients with active, unstable cardiovascular diseases, fits any of the following: 1. myocardial infarction within 6 months prior to the study enrollment 2. unstable angina within 3 months prior to the study enrollment 3. Uncontrolled clinically-significant conduction abnormalities (e.g., ventricular tachycardia, ventricular fibrillation, etc.) 4. Congestive heart failure (CHF) of New York Heart Association (NYHA) ≥ Grade 3 5. Echocardiography showing left ventricular ejection fraction less than 50% 8. Uncontrolled active infection within 1 week prior to the first dose of study drug. 9. Known active hepatitis B, or C infection or HIV infection; Note: Hepatitis B virus (HBV) surface antigen (HBsAg) and or hepatitis B core antibody-positive but undetectable HBV DNA or Hepatitis C virus (HCV) antibody positive but hepatitis C virus RNA undetectable are allowed. 10. Active GI dysfunction interfering with the ability to swallow tablets, or any GI dysfunction that could interfere with absorption of study treatment. 11. Prior exposure to a selective inhibitor of nuclear export(SINE) compound, including selinexor. 12. Serious, active psychiatric, or medical conditions which, in the opinion of the Investigator, could interfere with study treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Escalation: Recommended Phase 2 Does (RP2D) of Selinexor | Assessed from the date of first dose of study treatment to the first cycle ends (maximum 21days) | The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for the dose expansion arms, based on safety, tolerability, efficacy data collected during the dose escalation portion of the study |
| Dose Escalation: Maximum Tolerated Dose (MTD) of Selinexor | Assessed from the date of first dose of study treatment to the first cycle ends (maximum 21days) | The MTD will be determined by study definition as the highest dose level without significant safety and tolerability concern. |
| Objective Response Rate (ORR) | Cycle 1 Day 1 (each cycle consists of maximum 21 days) until a CR, CRu or PR (up to 18 cycles(each cycle is 21 days)). | ORR is defined as the proportion of patients with a best response of Complete remission (CR) or Unconfirmed(CRu), or PR during induction therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Adverse Events | From first dose of study drug administration to end of treatment (up to 18 cycles(each cycle is 21 days)) | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) |
| Progression-Free Survival (PFS) | up to 12 months | Duration from start of study treatment to PD or death (regardless of cause), whichever comes first |
| Duration of Response (DOR) | From first dose of study drug administration to end of treatment, up to 18 cycles(each cycle is 21 days) | Duration from the first observation of at least PR to time of progressive disease(PD), or deaths due to disease progression,whichever occurs first |
| Overall Survival (OS) | up to 12 months | Occurrence of death regardless of cause |
Other
| Measure | Time frame | Description |
|---|---|---|
| Gene mutations and frequency of 475 gene and whole exon | At baseline | The types of gene mutations and frequency of tumor are measured by whole exon sequencing via NGS(next-generation sequencing). |
| Circulating tumor DNA (ctDNA) in the CSF | At the baseline, day 1 at cycle 3, 5 (21days/cycle), and every 3 months in the maintenance stage (up to 1 year)) | The levels of ctDNA will be analyzed by next-generation sequencing. |
| The concentration of interleukin-10(IL-10)，interleukin-6(IL-6)，CXCL-13 cytokine in cerebrospinal fluid(CSF) | At the baseline, day 1 at cycle 3, 5 (21 days/cycle), and every 3 months in the maintenance stage (up to 1 year)) | The levels of cytokines will be analyzed by flow cytometry |
Countries
China
Contacts
Primary ContactTong Chen, Ph.D
Backup ContactYuan Yan, Ph.D
Outcome results
None listed